SCHEMBL4383356

SCHEMBL4383356

Cc1ccc(S(=O)(=O)OC[C@H](C)CC(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.43
CA1 P00915 4/20 0.43
CA9 Q16790 4/20 0.43
CA4 P22748 1/20 0.43
STAT3 P40763 1/20 0.40
GAA P10253 2/20 0.39
GBA1 P04062 1/20 0.38
CA7 P43166 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MDM2 Q00987 1/20 0.38
DHODH Q02127 1/20 0.37
CA12 O43570 2/20 0.37
VDR P11473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4383361 1.00 CA2 (0.43) CA2CA1CA9CA4STAT3
SCHEMBL2176311 0.90 GAA (0.45) CA2CA1CA9STAT3GAA
SCHEMBL4295792 0.87 CA2 (0.43) CA2CA1CA9CA4STAT3
SCHEMBL777474 0.86 GAA (0.45) CA2CA1CA9CA4STAT3
SCHEMBL6431507 0.85 CA2 (0.41) CA2CA1CA9STAT3GAA
SCHEMBL4202226 0.85 CA2 (0.41) CA2CA1CA9STAT3GAA
SCHEMBL4202231 0.85 CA2 (0.41) CA2CA1CA9STAT3GAA
SCHEMBL13096088 0.84 CA1 (0.41) CA2CA1CA9CA4STAT3
SCHEMBL9756838 0.83 STAT3 (0.43) CA2CA1CA9STAT3GAA
SCHEMBL9756774 0.83 STAT3 (0.43) CA2CA1CA9STAT3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090299093-A1 Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein PFIZER INC. 2009-12-03 US disclosed
EP-2017259-A2 Preparation of gamma-amino acids having affinity for the alpha-2-delta protein Pfizer Products Inc. (US) 2009-01-21 EP disclosed
CN-101341117-A Preparation of Y-amino acids having affinity for the alpha-2-delta protein PFIZER (US) 2009-01-07 CN disclosed
EP-1973867-A1 PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN Pfizer Products Inc. (US) 2008-10-01 EP disclosed
WO-2007072159-A1 PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN PFIZER PRODUCTS INC. (US) 2007-06-28 WO disclosed
US-20070141684-A1 Preparation of gamma-amino acids having affinity for the alpha-2-delta protein PFIZER INC 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070141684-A1 Preparation of gamma-amino acids having affinity for the alpha-2-delta protein SCN2A, CACNG2, SCN1A CA2 131/4885CA1 683/4885CA9 2575/4885
US-20090299093-A1 Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein SCN2A, CACNG2, SCN1A CA2 131/4885CA1 683/4885CA9 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.